An Early Phase 1 interventional study of Elagolix in Endometriosis, sponsored by Yale University. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Yale University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing elagolix in Endometriosis — 2 open to participants now, 4 under way, 2 of them phase 3. elagolix · Endometriosis.
Among the 22 studies testing elagolix in Endometriosis, this one is the 20th largest by enrollment, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 13th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →2 of the 22 studies testing elagolix in Endometriosis are open now, in 1 country. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 18–45 · Women only
Colorado State University
Ages 18–40 · Women only
By country, each count listing its studies:
elagolix: first FDA approval 2018 (ORILISSA). What it is approved for, and how studies give it, is on its page →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 165 across the 22 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 4 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
2 of the studies testing elagolix in Endometriosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing elagolix in Endometriosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
Drug: Elagolix
Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
Drug: Elagolix
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Flow Mediated Vasodilation
Blood flow velocity measured using the Sonoscope S2 ultrasound imaging system. Percent change is measured pre and post cuff inflation at baseline and during intervention
Time frame: Baseline and during intervention (1 month)
Microdialysis Perfusions of Acetylcholine ED50
Skin blood responses to perfusion of acetylcholine at baseline and during intervention
Time frame: Baseline and during intervention (1 month)
Microdialysis Perfusions of Acetylcholine Hill Slope
hill slope of skin blood flow dose perfusions of acetylcholine into skin
Time frame: baseline and during intervention (1 month)
Microdialysis Perfusions of Estradiol ED50
Skin blood responses to perfusion of estradiol at baseline and during intervention
Time frame: Baseline and during intervention (1 month)
Microdialysis Perfusions of Estradiol- Hill Slope
hill slope of skin blood flow dose perfusions of estradiol into skin
Time frame: Baseline and during intervention (1 month)
Plasma Estrogen Concentration
blood draw, this is done on baseline and during intervention
Time frame: Baseline and during intervention (1 month)
Serum Concentration Progesterone
Serum concentration progesterone at baseline and during intervention
Time frame: Baseline and During intervention (1 month)
Serum Sex Hormone Binding Globulin Concentration
Serum concentration of sex hormone binding globulin concentration taken a baseline and during intervention
Time frame: Baseline and During intervention (1 month)
Subjects were recruited using posters in the greater New Haven area, through advertisements on the Yale School of Medicine online listings for Clinical Research Studies for Volunteers, by contacting women who had consented to being contacted for future research through the Yale Center for Clinical Investigation for Clinical Research Studies and through Yale New Haven Hospital's MyChart system, through our laboratory and departmental websites and through social media.
| Milestone | Patients Without Endometriosis | Patients With Endometriosis |
|---|---|---|
| Started | 13 | 8 |
| Completed | 12 | 8 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Blood flow velocity measured using the Sonoscope S2 ultrasound imaging system. Percent change is measured pre and post cuff inflation at baseline and during intervention
| percent change | Patients Without Endometriosis | Patients With Endometriosis |
|---|---|---|
| Baseline | 12.5 ± 4.25 | 9.49 ± 4.17 |
| During intervention | 9.57 ± 4.57 | 7.62 ± 4.19 |
Skin blood responses to perfusion of acetylcholine at baseline and during intervention
| log M | Patients Without Endometriosis | Patients With Endometriosis |
|---|---|---|
| Baseline | -3.38 ± 1.08 | -2.83 ± 1.20 |
| During intervention | -2.49 ± 0.89 | -3.49 ± 1.50 |
hill slope of skin blood flow dose perfusions of acetylcholine into skin
| Moles/%variability | Patients Without Endometriosis | Patients With Endometriosis |
|---|---|---|
| Baseline | 1.38 ± 2.20 | 2.35 ± 1.80 |
| During intervention | 2.31 ± 1.85 | 2.78 ± 1.43 |
blood draw, this is done on baseline and during intervention
| pg/ml | Women Without Endometriosis | Women With Endometriosis |
|---|---|---|
| Baseline | 24.4 ± 15.9 | 13.7 ± 4.4 |
| During intervention | 24.4 ± 15.9 | 13.7 ± 4.4 |
Serum concentration progesterone at baseline and during intervention
| ng/ml | Women Without Endometriosis | Women With Endometriosis |
|---|---|---|
| Baseline | 0.9 ± 0.4 | 1.3 ± 0.6 |
| During intervention | 0.9 ± 0.3 | 0.9 ± 0.7 |
Serum concentration of sex hormone binding globulin concentration taken a baseline and during intervention
| nmol/L | Women Without Endometriosis | Women With Endometriosis |
|---|---|---|
| Baseline | 197 ± 43 | 144 ± 60 |
| During intervention | 198 ± 42 | 37 ± 55 |
Skin blood responses to perfusion of estradiol at baseline and during intervention
| nanoMolar | Patients Without Endometriosis | Patients With Endometriosis |
|---|---|---|
| Baseline | 1.88 ± 0.08 | 1.95 ± 0.24 |
| During interventions | 1.80 ± 0.13 | 2.90 ± 0.27 |
hill slope of skin blood flow dose perfusions of estradiol into skin
| nanoMolar/L | Patients With Endometriosis | Patients Without Endometriosis |
|---|---|---|
| Baseline | 40.49 ± 5.83 | 3.29 ± 4.83 |
| During intervention | 7.97 ± 5.83 | 6.88 ± 4.55 |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients Without Endometriosis | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Patients With Endometriosis | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
Baseline characteristics provided for all participants that completed.
| Age, Categorical(Participants) | Patients Without Endometriosis | Patients With Endometriosis | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 8 | 20 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Patients Without Endometriosis | Patients With Endometriosis | Total |
|---|---|---|---|
| Female | 12 | 8 | 20 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Patients Without Endometriosis | Patients With Endometriosis | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 11 | 7 | 18 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Patients Without Endometriosis | Patients With Endometriosis | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 7 | 5 | 12 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Patients Without Endometriosis | Patients With Endometriosis | Total |
|---|---|---|---|
| United States | 12 | 8 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in May 2025, 34 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 34 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2025 → May 2025 and completion Dec 2026 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elagolix